Literature DB >> 35212878

Effects and Trends in Opioid-Related Promotional Payments Between 2014 and 2019: a Panel Data Analysis Among Prescribers in Medicare Part D.

Elle Pope1, Neil Sehgal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35212878      PMCID： PMC9550901          DOI： 10.1007/s11606-022-07457-w

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   6.473


× No keyword cloud information.
  4 in total

1.  Pharmaceutical payments to physicians may increase prescribing for opioids.

Authors:  Thuy D Nguyen; W David Bradford; Kosali I Simon
Journal:  Addiction       Date:  2019-01-22       Impact factor: 6.526

2.  Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation.

Authors:  Jonathan H Marks
Journal:  J Bioeth Inq       Date:  2020-07-13       Impact factor: 1.352

3.  Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing.

Authors:  Ian Larkin; Desmond Ang; Jonathan Steinhart; Matthew Chao; Mark Patterson; Sunita Sah; Tina Wu; Michael Schoenbaum; David Hutchins; Troyen Brennan; George Loewenstein
Journal:  JAMA       Date:  2017-05-02       Impact factor: 56.272

4.  Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing.

Authors:  Mark A Zezza; Marcus A Bachhuber
Journal:  PLoS One       Date:  2018-12-19       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.